Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Literature DB >> 22748660

Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Daniel T Nagasawa¹, Christina Fong, Andrew Yew, Marko Spasic, Heather M Garcia, Carol A Kruse, Isaac Yang.

Abstract

This review provides historical and recent perspectives related to passive immunotherapy for high-grade gliomas. The authors discuss approaches that use lymphokine-activated killer cells, cytotoxic T lymphocytes, and monoclonal antibodies.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
Antibodies, Monoclonal

Year: 2012 PMID： 22748660 PMCID： PMC3994467 DOI： 10.1016/j.nec.2012.04.008

Source DB: PubMed Journal: Neurosurg Clin N Am ISSN： 1042-3680 Impact factor: 2.509

133 in total

Review 1. Bevacizumab at recurrence in high-grade glioma.

Authors: Andrea Salmaggi; Paola Gaviani; Andrea Botturi; Elena Lamperti; Giorgia Simonetti; Daniela Ferrari; Antonio Silvani
Journal: Neurol Sci Date: 2011-11 Impact factor: 3.307

Review 2. Progress in active specific immunotherapy of prostate cancer.

Authors: B A Tjoa; G P Murphy
Journal: Semin Surg Oncol Date: 2000 Jan-Feb

3. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.

Authors: Weilian Yang; Rolf F Barth; Gong Wu; Shinji Kawabata; Thomas J Sferra; Achintya K Bandyopadhyaya; Werner Tjarks; Amy K Ferketich; Melvin L Moeschberger; Peter J Binns; Kent J Riley; Jeffrey A Coderre; Michael J Ciesielski; Robert A Fenstermaker; Carol J Wikstrand
Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531

4. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.

Authors: P A Humphrey; L M Gangarosa; A J Wong; G E Archer; M Lund-Johansen; R Bjerkvig; O D Laerum; H S Friedman; D D Bigner
Journal: Biochem Biophys Res Commun Date: 1991-08-15 Impact factor: 3.575

5. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

Authors: R O Dillman; C Church; R K Oldham; W H West; L Schwartzberg; R Birch
Journal: Cancer Date: 1993-04-01 Impact factor: 6.860

6. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.

Authors: A Blancher; F Roubinet; A S Grancher; M Tremoulet; A Bonaté; M B Delisle; J P Calot; C Pourreau; C Franks; J Ducos
Journal: Eur Cytokine Netw Date: 1993 Sep-Oct Impact factor: 2.737

Review 7. Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

Authors: Minhtran C Ngo; Cliona M Rooney; Jeffrey M Howard; Helen E Heslop
Journal: Hum Mol Genet Date: 2011-03-17 Impact factor: 6.150

8. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.

Authors: P Riva; G Franceschi; A Arista; M Frattarelli; N Riva; A M Cremonini; G Giuliani; M Casi
Journal: Cancer Date: 1997-12-15 Impact factor: 6.860

Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Review 1. Bevacizumab at recurrence in high-grade glioma.

Review 2. Progress in active specific immunotherapy of prostate cancer.

3. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.

4. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.

5. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

6. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.

Review 7. Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

8. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.

9. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.

Review 10. Overview of cellular immunotherapy for patients with glioblastoma.

Review 1. NKp30 - A prospective target for new cancer immunotherapy strategies.

Review 2. Receptor-Targeted Glial Brain Tumor Therapies.

Review 3. Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.

Review 4. T Cell Epitope Prediction and Its Application to Immunotherapy.